About scilex holding co - SCLX
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
SCLX At a Glance
Scilex Holding Co.
960 San Antonio Road
Palo Alto, California 94303
| Phone | 1-650-516-4310 | Revenue | 56.59M | |
| Industry | Pharmaceuticals: Other | Net Income | -72,807,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 21.066% | |
| Fiscal Year-end | 12 / 2025 | Employees | 115 | |
| View SEC Filings |
SCLX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.988 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 2.89 |
| Enterprise Value to EBITDA | -1.098 |
| Enterprise Value to Sales | 1.721 |
| Total Debt to Enterprise Value | 0.46 |
SCLX Efficiency
| Revenue/Employee | 492,086.957 |
| Income Per Employee | -633,104.348 |
| Receivables Turnover | 2.14 |
| Total Asset Turnover | 0.583 |
SCLX Liquidity
| Current Ratio | 0.137 |
| Quick Ratio | 0.128 |
| Cash Ratio | 0.013 |
SCLX Profitability
| Gross Margin | 63.359 |
| Operating Margin | -163.964 |
| Pretax Margin | -128.659 |
| Net Margin | -128.657 |
| Return on Assets | -74.958 |
| Return on Equity | N/A |
| Return on Total Capital | 49.233 |
| Return on Invested Capital | N/A |
SCLX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -30.266 |
| Total Debt to Total Assets | 48.151 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -3.417 |